I. Molnár

发表

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

R. Paschke, L. Bastholt, M. Schlumberger, 2014, The Lancet.

What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?

B. Powell, I. Molnár, 2007, Current hematologic malignancy reports.

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer

B. Melichar, I. Láng, T. Csoszi, 2017, Clinical pharmacology and therapeutics.

Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis

J. Dutcher, J. Knox, S. Bracarda, 2013, British Journal of Cancer.

Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.

R. Paschke, L. Bastholt, M. Schlumberger, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

B. Hendriks, A. Shields, P. LoRusso, 2018, British Journal of Cancer.

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

S. Verma, D. Tripathy, D. Yardley, 2016, BMC Cancer.

The association between serum copper and anaemia in the adult Second National Health and Nutrition Examination Survey (NHANES II) population

A. Ivanova, D. Il'yasova, I. Molnár, 2008, British Journal of Nutrition.

Association between tumor BRAF and RAS mutation status and clinical outcomes in patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) randomized to sorafenib or placebo: sub-analysis of the phase III DECISION trial

R. Paschke, M. Schlumberger, M. Jeffers, 2014 .

Abstract CT234: A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+ metastatic breast cancer

B. Hendriks, A. Shields, P. LoRusso, 2015 .

Copper deficiency causes reversible myelodysplasia

D. Hurd, Y. Keung, I. Molnár, 2007, American journal of hematology.

Addition of sargramostim (GM-CSF) to imatinib results in major cytogenetic response in a patient with chronic myeloid leukemia.

P. Koty, D. Hurd, M. Pettenati, 2006, Leukemia research.

Studies on coagulation, fibrinolysis, kallikrein-kinin and complement activation in systemic and pulmonary circulation during hip arthroplasty with acrylic cement.

P. Kierulf, H. Prydz, I. Molnár, 1988, Thrombosis research.

19-Nor-1α,25-dihydroxyvitamin D2 (paricalcitol) exerts anticancer activity against HL-60 cells in vitro at clinically achievable concentrations

M. Willingham, G. Schwartz, T. Kute, 2004, The Journal of Steroid Biochemistry and Molecular Biology.

19-Nor-1α,25-dihydroxyvitamin D2 (paricalcitol): effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines

M. Willingham, G. Schwartz, T. Kute, 2003, Journal of Cancer Research and Clinical Oncology.

Generalized granuloma annulare as an initial manifestation of chronic myelomonocytic leukemia: a report of 2 cases.

G. Yosipovitch, D. Sheehan, I. Molnár, 2008, The American Journal of dermatopathology.

Arthritis Associated with Recurrent Erythema Multiforme Responding to Oral Acyclovir

I. Molnár, M. Matulis, 2002, Clinical Rheumatology.

Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature.

M. Pettenati, B. Powell, D. Buss, 2004, Leukemia research.

Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer

B. Sherrill, B. Sherif, I. Molnár, 2012, International Journal of Colorectal Disease.

Breast carcinoma subtypes show different patterns of metastatic behavior

B. Ács, J. Moldvay, B. Szekely, 2017, Virchows Archiv.

Global tests on coagulation and fibrinolysis in systemic and pulmonary circulation accompanying hip arthroplasty with acrylic cement.

I. Molnár, O. Dahl, J. Rø, 1988, Thrombosis research.

The transplant iron score as a predictor of stem cell transplant survival

J. Lovato, F. Torti, S. Torti, 2009, Journal of Hematology & Oncology.

Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy

B. Ács, A. Tőkés, G. Szentmártoni, 2017, Diagnostic Pathology.

Intrapulmonary thrombin generation and its relation to monomethylmethacrylate plasma levels during hip arthroplasty

P. Mowinckel, P. Kierulf, I. Molnár, 1992, Acta anaesthesiologica Scandinavica.

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

S. Verma, D. Tripathy, D. Yardley, 2016, BMC Cancer.

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

B. Hendriks, A. Shields, P. LoRusso, 2018, British Journal of Cancer.

Copper Deficiency Anemia Is Not Uncommon in a Hematology Practice.

Y. Keung, I. Molnár, J. Owen, 2005 .

Treatment of low-risk myelodysplastic syndromes with high-dose daily oral cholecalciferol (2000–4000 IU vitamin D3)

J. Lovato, T. Chen, G. Schwartz, 2007, Leukemia.

[Hypercoagulability syndrome associated with cerebral lesions. Prospective study of coagulation during surgery of primary brain tumors (17 cases)].

A. Safran, I. Molnár, J. Berney, 1986, Neuro-Chirurgie.

Celiac plexus block increases quality of life in patients with pancreatic cancer

H. Szőke, Z. Kovács, J. Vagedes, 2019, Journal of pain research.

Pharmacokinetics of alemtuzumab and the relevance in clinical practice

J. Kuhlmann, M. Hallek, C. Wendtner, 2008, Leukemia & lymphoma.

Novel innate cancer killing activity in humans

M. Willingham, J. Lovato, W. Du, 2011, Cancer Cell International.

Treatment of post-transplant lymphoproliferative disorder with rituximab and radiation in a patient with second renal allograft.

Y. Keung, I. Molnár, 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial.

R. Paschke, L. Bastholt, M. Schlumberger, 2014 .

MITOXANTRONE FOR MULTIPLE SCLEROSIS CAUSING ACUTE LYMPHOBLASTIC LEUKEMIA

D. R. Jeffery, P. Koty, D. Jeffery, 2007, Neurology.

YNSA permanent acupuncture of on quality of life in patients suffering from post-stroke syndrome

H. Szőke, G. Hegyi, I. Molnár, 2018 .

Constitutional t(8;22) in a patient with myasthenia gravis, leukocytosis, and thrombocytosis.

M. Pettenati, Y. Keung, I. Molnár, 2004, Cancer genetics and cytogenetics.

Prognostic and predictive factors correlated with treatment outcomes for radioactive iodine-refractory differentiated thyroid cancer (RAI-RDTC) patients receiving Sorafenib or placebo on the phase III decision trial

R. Paschke, L. Bastholt, M. Schlumberger, 2015 .

Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial.

R. Paschke, L. Bastholt, M. Schlumberger, 2014 .

Safety and tolerability of sorafenib for treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC): Detailed analyses from the phase III DECISION trial.

M. Fassnacht, M. Schlumberger, C. Nutting, 2014 .

Advanced glycation end products and their soluble receptor (sRAGE) in patients with Hashimoto’s thyroiditis on levothyroxine substitution

G. Paragh, M. Harangi, I. Molnár, 2023, Frontiers in Endocrinology.

A phase I study of [225Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors.

F. Saad, J. Valliant, R. Juergens, 2019, Journal of Clinical Oncology.

Epidural analgesia and anticoagulant therapy

I. Molnár, J. Rø, 1984, Anaesthesia.

Effects of neural therapy on quality of life in patients suffering from Raynaud syndrome

H. Szőke, G. Hegyi, I. Molnár, 2018 .

YNSA permanent acupuncture application for post-stroke syndrome

H. Szőke, G. Hegyi, I. Molnár, 2018 .

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

B. Hendriks, A. Shields, P. LoRusso, 2018, British Journal of Cancer.

The Transfusion Iron Overload Score Is a Potential Predictor of Survival in Stem Cell Transplant Patients.

J. Lovato, F. Torti, D. Hurd, 2007 .

Exploratory analysis of outcomes for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-RDTC) receiving open-label Sorafenib post-progression on the phase III decision trial

R. Paschke, L. Bastholt, M. Schlumberger, 2015 .